<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2022-2-4-34-40</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE NEOPLASMS: COMPLEX CLINICAL SITUATIONS AND SELECTION OF TREATMENT TACTICS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ НОВООБРАЗОВАНИЯ: СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primary cutaneous diffuse large B-cell lymphoma, leg type, in an 80-year-old female patient. Clinical case</article-title><trans-title-group xml:lang="ru"><trans-title>Первичная кожная диффузная В-крупноклеточная лимфома, тип «нижние конечности» (leg type), у пациентки 80 лет. Клиническое наблюдение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8443-8816</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryabukhina</surname><given-names>Yu. E.</given-names></name><name xml:lang="ru"><surname>Рябухина</surname><given-names>Ю. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Yulia E. Ryabukhina.</p><p>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>Рябухина Юлия Евгеньевна.</p><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><email>gemonk.yur@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2359-0547</contrib-id><name-alternatives><name xml:lang="en"><surname>Abbasbeyli</surname><given-names>F. M.</given-names></name><name xml:lang="ru"><surname>Аббасбейли</surname><given-names>Ф. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6229-7300</contrib-id><name-alternatives><name xml:lang="en"><surname>Timofeeva</surname><given-names>O. L.</given-names></name><name xml:lang="ru"><surname>Тимофеева</surname><given-names>О. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111;</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University).</p><p>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081; Bld. 2, 8 Trubetskaya St., Moscow 119991</p></bio><bio xml:lang="ru"><p>Кафедра онкологии ПМГМУ им. И.М. Сеченова МЗ РФ (Сеченовский Университет).</p><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111; 119991 Москва, ул. Трубецкая, 8, стр. 2</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5353-8857</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhukov</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Жуков</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2022</year></pub-date><volume>2</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>34</fpage><lpage>40</lpage><history><date date-type="received" iso-8601-date="2022-11-03"><day>03</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-13"><day>13</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, АБВ-пресс</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/53">https://mdonco.abvpress.ru/jour/article/view/53</self-uri><abstract xml:lang="en"><p>Primary cutaneous diffuse large B-cell lymphoma, leg type, is diagnosed in 20-25 % cases of all primary cutaneous B-cell lymphomas, primarily in elderly women (older than 70 years). The disease has aggressive recurrent progression and worse prognosis than other variants. The standard antitumor drug therapy are such regimens as R-CHOP and CHOP-like programs including anthracycline antibiotics. Use of these programs can be limited by the presence of cardiovascular and other concomitant disorders.</p><p>Due to the limited variety of combinations of antitumor agents, low frequency of diagnosis of this immunomorphological variant of lymphoproliferative disease and absence of a single algorithm of drug therapy, every clinical case is interesting and informative.</p><p>In the presented clinical case, an 80-year-old female patient with primary cutaneous diffuse large B-cell lymphoma, leg type, and concomitant pathology of the cardiovascular system underwent 2 courses of R-CVP regimen drug therapy without anthracyclines. A significant antitumor clinical effect was achieved in the form of complete tumor regression. Treatment was not accompanied by significant toxicity which allowed to complete therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Первичная кожная диффузная В-крупноклеточная лимфома, тип «нижние конечности», диагностируется в 20-25 % случаев всех первичных кожных В-клеточных лимфом, преимущественно у женщин пожилого возраста (старше 70 лет). Заболевание имеет агрессивное рецидивирующее течение и отличается от других вариантов худшим прогнозом. Стандартом противоопухолевой лекарственной терапии являются такие режимы, как R-CHOP и CHOP-подобные программы, включающие антибиотики антрациклинового ряда. Применение этих программ может ограничивать наличие сердечно-сосудистых и других сопутствующих заболеваний.</p><p>Из-за ограниченного выбора комбинаций противоопухолевых агентов, небольшой частоты выявления данного иммуноморфологического варианта лимфопролиферативного заболевания и отсутствия единого алгоритма лекарственной терапии каждое клиническое наблюдение вызывает несомненный интерес.</p><p>В представленном клиническом наблюдении пациентке 80 лет с первичной кожной диффузной В-крупноклеточной лимфомой, тип «нижние конечности», и сопутствующей патологией сердечно-сосудистой системы было проведено 2 курса лекарственной терапии в режиме R-CVP без антрациклинов. Достигнут выраженный противоопухолевый клинический эффект в виде полной регрессии опухоли. Лечение не сопровождалось развитием значимой токсичности, что позволило продолжить терапию в полном объеме.</p></trans-abstract><kwd-group xml:lang="en"><kwd>primary cutaneous diffuse large B-cell lymphoma</kwd><kwd>leg type</kwd><kwd>antitumor drug therapy</kwd><kwd>anthracycline antibiotics</kwd><kwd>cardiotoxicity</kwd><kwd>R-CVP regimen</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>первичная кожная диффузная В-крупноклеточная лимфома</kwd><kwd>тип «нижние конечности»</kwd><kwd>противоопухолевая лекарственная терапия</kwd><kwd>антибиотики антрациклинового ряда</kwd><kwd>кардиотоксичность</kwd><kwd>режим R-CVP</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1.	Willemze R., Cerroni L., Kempf W. et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133(16):1703-14. DOI: 10.1182/blood-2018-11-881268</mixed-citation><mixed-citation xml:lang="ru">Willemze R., Cerroni L., Kempf W. et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133(16):1703-14. DOI: 10.1182/blood-2018-11-881268</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Al-Obaidi A., Parker N.A., Choucair K. et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: a case report. Cureus 2020;12(6):e8651. DOI 10.7759/cureus.8651</mixed-citation><mixed-citation xml:lang="ru">Al-Obaidi A., Parker N.A., Choucair K. et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: a case report. Cureus 2020;12(6):e8651. DOI 10.7759/cureus.8651</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol 2015;90(5):687-706. DOI: 10.1590/abd1806-4841.20153638</mixed-citation><mixed-citation xml:lang="ru">Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol 2015;90(5):687-706. DOI: 10.1590/abd1806-4841.20153638</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Sokol L., Naghashpour M., Glass L.F. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control 2012;19(3):236-44. DOI: 10.1177/107327481201900308</mixed-citation><mixed-citation xml:lang="ru">Sokol L., Naghashpour M., Glass L.F. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control 2012;19(3):236-44. DOI: 10.1177/107327481201900308</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Coiffier B. When can R-CHOP not be used in an elderly patient? Oncology (Williston Park) 2013;27(2):146-8.</mixed-citation><mixed-citation xml:lang="ru">Coiffier B. When can R-CHOP not be used in an elderly patient? Oncology (Williston Park) 2013;27(2):146-8.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Guyot A., Ortonne N., Valeyrie-Allanore L., Bagot M. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. Arch Dermatol 2010;146(1):89-91. DOI: 10.1001/archdermatol.2009.345</mixed-citation><mixed-citation xml:lang="ru">Guyot A., Ortonne N., Valeyrie-Allanore L., Bagot M. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. Arch Dermatol 2010;146(1):89-91. DOI: 10.1001/archdermatol.2009.345</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Pulini S., Rupoli S., Goteri G. et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol 2009;82(3):184-93. DOI: 10.1111/j.1600-0609.2008.01197.x</mixed-citation><mixed-citation xml:lang="ru">Pulini S., Rupoli S., Goteri G. et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol 2009;82(3):184-93. DOI: 10.1111/j.1600-0609.2008.01197.x</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Grange F., Joly P., Barbe C. et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014;150(5):535-41. DOI: 10.1001/jamadermatol.2013.7452</mixed-citation><mixed-citation xml:lang="ru">Grange F., Joly P., Barbe C. et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014;150(5):535-41. DOI: 10.1001/jamadermatol.2013.7452</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Beylot-Barry M., Mermin D., Maillard A. et al. A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 2018;138(9):1982-9. DOI: 10.1016/j.jid.2018.03.1516</mixed-citation><mixed-citation xml:lang="ru">Beylot-Barry M., Mermin D., Maillard A. et al. A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 2018;138(9):1982-9. DOI: 10.1016/j.jid.2018.03.1516</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Gupta E., Accurso J., Sluzevich J. et al. Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Rare Tumors 2015;7(4):164-6. DOI: 10.4081/rt.2015.6067</mixed-citation><mixed-citation xml:lang="ru">Gupta E., Accurso J., Sluzevich J. et al. Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Rare Tumors 2015;7(4):164-6. DOI: 10.4081/rt.2015.6067</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Menguy S., Prochazkova-Carlotti M., Beylot-Barry M. et al. PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 2018;42(3):326-34. DOI: 10.1097/PAS.0000000000000983</mixed-citation><mixed-citation xml:lang="ru">Menguy S., Prochazkova-Carlotti M., Beylot-Barry M. et al. PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 2018;42(3):326-34. DOI: 10.1097/PAS.0000000000000983</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Di Raimondo C., Abdulla F.R., Zain J. et al. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol 2019;187(3):e79-e82. DOI: 10.1111/bjh.16211</mixed-citation><mixed-citation xml:lang="ru">Di Raimondo C., Abdulla F.R., Zain J. et al. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol 2019;187(3):e79-e82. DOI: 10.1111/bjh.16211</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Tadiotto Cicogna G., Ferranti M., Lazzarotto A., Alaibac M. Biological approaches to aggresive cutaneous B-cell lymphomas. Front Oncol 2019;9:1-4. DOI: 10.3389/fonc.2019.01238</mixed-citation><mixed-citation xml:lang="ru">Tadiotto Cicogna G., Ferranti M., Lazzarotto A., Alaibac M. Biological approaches to aggresive cutaneous B-cell lymphomas. Front Oncol 2019;9:1-4. DOI: 10.3389/fonc.2019.01238</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Mareschal S., Pham-Ledard A., Viailly P.J. et al. Identification of somatic mutations in primary cutaneous diffuse large B-Cell Lymphoma, leg type by massive parallel sequencing. J Investig Dermatol 2017;137(9):1984-94. DOI: 10.1016/j.jid.2017.04.010</mixed-citation><mixed-citation xml:lang="ru">Mareschal S., Pham-Ledard A., Viailly P.J. et al. Identification of somatic mutations in primary cutaneous diffuse large B-Cell Lymphoma, leg type by massive parallel sequencing. J Investig Dermatol 2017;137(9):1984-94. DOI: 10.1016/j.jid.2017.04.010</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15.	Pham-Ledard A.; Prochazkova-Carlotti M., Andrique L. et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2014;27(3):402-11. DOI: 10.1038/modpathol.2013.156</mixed-citation><mixed-citation xml:lang="ru">Pham-Ledard A.; Prochazkova-Carlotti M., Andrique L. et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2014;27(3):402-11. DOI: 10.1038/modpathol.2013.156</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16.	Mitteldorf C., Berisha A., Pfaltz M. et al. Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma - new therapeutic targets. Am J Surg Pathol 2017;41(7):998-1004. DOI: 10.1097/PAS.0000000000000851</mixed-citation><mixed-citation xml:lang="ru">Mitteldorf C., Berisha A., Pfaltz M. et al. Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma - new therapeutic targets. Am J Surg Pathol 2017;41(7):998-1004. DOI: 10.1097/PAS.0000000000000851</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Schmittlutz K., Marks R. Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Ther Adv Hematol. 2021;12:2040 620721996484. DOI: 10.1177/2040620721996484</mixed-citation><mixed-citation xml:lang="ru">Schmittlutz K., Marks R. Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Ther Adv Hematol. 2021;12:2040 620721996484. DOI: 10.1177/2040620721996484</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Hershman D.L., McBride R.B., Eisenberger A. et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(19):3159-65. DOI: 10.1200/JCO.2007.14.1242</mixed-citation><mixed-citation xml:lang="ru">Hershman D.L., McBride R.B., Eisenberger A. et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(19):3159-65. DOI: 10.1200/JCO.2007.14.1242</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Wieringa A., Boslooper K., Hoogendoorn M. et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165(4):489-96. DOI: 10.1111/bjh.12765</mixed-citation><mixed-citation xml:lang="ru">Wieringa A., Boslooper K., Hoogendoorn M. et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165(4):489-96. DOI: 10.1111/bjh.12765</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	Laribi K., Denizon N., Bolle D. et al. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol 2016;95(10):1705-14. DOI: 10.1007/s00277-016-2768-x</mixed-citation><mixed-citation xml:lang="ru">Laribi K., Denizon N., Bolle D. et al. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol 2016;95(10):1705-14. DOI: 10.1007/s00277-016-2768-x</mixed-citation></citation-alternatives></ref></ref-list></back></article>
